Megan McCann Discusses Risk of Breast Cancer Among Young Women
Women under 40 who find a suspicious lump in their breast often have their cancer fears dismissed and are told “you are too young for breast cancer,” according to Megan McCann, associate director of programs at the Young Survival Coalition. Here, she discusses breaking down that misconception that younger women can’t get breast cancer.
Women under 40 who find a suspicious lump in their breast often have their cancer fears dismissed and are told “you are too young for breast cancer,” according to Megan McCann, associate director of programs at the Young Survival Coalition. Here, she discusses breaking down that misconception that younger women can’t get breast cancer.
About 13,000 women under 40 are diagnosed with breast cancer every year. McCann emphasizes the importance of women being their own advocates, because after all, they know their own body best.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
